Humacyte was riding high in December 2024 when it secured an FDA green light for a groundbreaking implant. Now, as it looks ...

Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - - First quarter sales of Symvess® were ...

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago. These figures are ...

Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech ...

Humacyte (NASDAQ:HUMA) reported first-quarter 2026 Symvess sales of $0.5 million and outlined a series of commercial, ...

Humacyte reported Q1 2026 financial results showing sales increased to $500,000 in Q1 2025, but the biotech company is ...

Humacyte (NASDAQ:HUMA) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, ...

Humacyte (NASDAQ:HUMA) outlined the unmet need in hemodialysis vascular access and highlighted data from its clinical program evaluating the company’s acellular tissue engineered vessel (ATEV) as an ...

Thank you, Tom, and good morning, everyone, and thank you for joining us for our first quarter financial results and business update call for 2026. To remind this audience, Humacyte's key corporate ...

On April 21, 2026, Humacyte entered a third amendment to its distribution agreement with Fresenius Medical Care, regaining sole global rights to develop, commercialize and manage regulatory matters ...

DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...